Introduction
Despite improvements in understanding of the pathophysiology of heart failure (HF) and significant progress in pharmacological therapy, the disease remains a substantial cause of morbidity and mortality and a considerable global burden for healthcare systems.
1 -4 Prescription of evidence-based therapies recommended by international guidelines is the most effective way of ensuring that patients receive optimal care. 5 Although physicians are encouraged to implement such guidelines in practice, it has been repeatedly observed that a sizeable proportion of HF patients do not receive evidence-based treatments. A study analysing care delivered to over 15 000 HF patients in outpatient settings found that a median of 27% of patients received all HF therapies for which they were potentially eligible, and use of guideline-recommended therapies varied widely between practice settings. 6 More recently, data from the National Heart Failure Audit of nearly 57 000 HF admissions in England and Wales in [2014] [2015] showed that only 42% of HF patients were discharged on angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), beta-blockers (BBs) and mineralocorticoid receptor antagonists (MRAs). 7 There is some evidence that good adherence to guidelines can improve clinical outcomes. For example, in a multicentre, observational study on the medical management and cost of chronic HF carried out in six European countries between 2001 and 2002, adherence to treatment guidelines was a strong predictor of fewer cardiovascular (CV) hospitalizations. 8 However, even when prescription of guideline-based HF treatment is high, there is evidence of frequent failure to reach target doses 9 and there is evidence from some, though not all studies, that sub-optimal dosing may adversely influence outcomes.
10,11
We therefore decided to gain a global perspective on the impact of adherence to guideline-recommended medication for HF, including prescription of recommended doses, on clinical outcomes. The international survey QUALIFY (QUality of Adherence to guideline recommendations for LIFe-saving treatment in heart failure surveY) assessed adherence to five classes of medications recommended for HF with reduced ejection fraction (HFrEF) by the European Society of Cardiology (ESC) guidelines, ACEIs, ARBs, BBs, MRAs and ivabradine. 12 We have previously reported baseline characteristics and guideline adherence scores for the study population at enrollment. 13 In the present analysis, we report the impact of physicians' adherence to the same guideline-recommended classes of HF medication, including prescription of recommended doses, on clinical outcomes at 6-month follow-up.
Methods

Study design and population
QUALIFY is an international, prospective, observational, longitudinal survey of outpatients with HFrEF treated at 547 centres in 36 countries in Africa, Asia, Australia, Europe, the Middle East, and North, Central and South America.
Survey participants were adult outpatients (>18 years old) with chronic HF diagnosed according to the participating investigator's . clinical judgement, with left ventricular ejection fraction (LVEF) ≤40% (on the most recent echocardiogram, ≤2 years), who had been hospitalized for worsening HF within the previous 1-15 months. Information collected at baseline included demographics, medical history, CV risk factors and lifestyle, results of physical examination, current symptoms, most recently available investigations, including electrocardiogram, echocardiography and laboratory data, and current medical treatments. Details of the study design, baseline evaluation and data management have been published previously. 13 The survey involved physicians and we assessed physicians' adherence to guideline-recommended medications in HFrEF. 13 Key clinical outcomes assessed at 6-month follow-up were all-cause mortality, CV death, HF death, HF hospitalization, HF hospitalization or HF death, CV hospitalization or CV death. Events were reported by investigators and were not centrally adjudicated. Between 10% and 15% of the centres in each country were audited as a means of face-to-face quality control (1397 patients in total at baseline and follow-up visits). Data in source documents were compared with data recorded and the results of the audit were satisfactory in most cases. When quality control problems occurred, a face-to-face discussion was organized with investigators and cross checks made between source documents and recorded data.
Global adherence to guideline score
The global adherence to guideline score used in QUALIFY was based on physicians' adherence to the latest ESC HF guideline recommendations at the time the study registry was established. 12 The score related to five classes of medications associated with significant improvement in morbidity or mortality in large randomised controlled trials (RCTs), and recommended by the ESC for reduction of mortality and/or HF hospitalization: ACEIs, ARBs (if ACEIs not tolerated), BBs, MRAs [if New York Heart Association (NYHA) class II-IV] and ivabradine (sinus rhythm, heart rate ≥70 or 75 b.p.m., NYHA class II-IV). 12 Having previously identified under-dosage of recommended medications as an issue in our baseline QUALIFY analysis, 13 we integrated adherence to target doses of recommended medications into the adherence score for the current 6-month outcome analysis.
The adherence score was the ratio of the treatment actually prescribed to the treatment that should theoretically have been prescribed. The theoretical treatment score was calculated for every patient, taking into account treatment eligibility criteria, guideline-based contraindications to drugs or treatments and use in ≥50% of recommended dosages ( Table S1 ). The number of patients prescribed medication at ≥50% target dose was assessed using doses defined by the ESC guidelines when available; 12 for ivabradine, we used the therapeutic regimen used in the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT). 14 The score was calculated for each patient by summing the points attributed as follows: 0 points for non-prescription in the absence of contraindications, 0.5 points for use of <50% of target dosage (<100% of target dose for MRA as the majority of patients were treated with ≥50% of target dose of MRA) or 1 point for use in ≥50% of target dosage (target dose for MRA). Non-administration of recommended drugs due to specific contraindications or intolerance was scored as adherence to guidelines. The score ranged from 0 (very poor) to 1 (excellent) and we defined three levels of adherence: good adherence (score =1); moderate adherence (score >0.5 to <1) and poor adherence (score ≤0.5). In this survey, our term 'adherence' relates solely to physicians following guidelines, not to patient compliance or persistence.
screened 7117 analysed at baseline
Excluded from baseline population n=139 (1.9%) Reasons for exclusion (multiple reasons possible) : Discharge from hospital admission for HF ≤1 month (n=65) Discharge from hospital admission for HF ≥15 months (n=48) Non-compliant: not signed informed consent (n=3) No information on medications (n=25)
analysed at 6 months
Patients without follow-up n=448 Figure 1 Study population. HF, heart failure.
The survey was conducted according to the rules of the declaration of Helsinki and was approved by relevant ethics committees and/or regulatory bodies in all 36 participating countries. All patients gave written informed consent to participate, in accordance with national and local regulations. The QUALIFY survey is registered in the ISRCTN registry of clinical trials under the number ISRCTN87465420.
Statistical analysis
This analysis has been conducted in patients with 6-month follow-up information and known adherence score at baseline. Baseline characteristics for three adherence groups -good (score =1), moderate (score >0.5 to <1) and low (score ≤0.5) are presented using descriptive statistics as numbers and percentages for categorical variables, and means ± standard deviation or median for continuous variables. Baseline values were compared between groups using an analysis of variance (ANOVA) test for quantitative variables and chi-square test or Fisher's exact test for qualitative variables.
Individual and composite clinical outcomes were analysed based on the time to first event. The data were analysed using Cox proportional hazards regression models to calculate hazard ratios (HRs), corresponding 95% confidence intervals (CIs), and P-values, for each adherence group.
Univariate analysis was conducted using potential covariates such as age, gender, time to HF diagnosis, coronary artery disease, diabetes, . hypertension, asthma/chronic obstructive pulmonary disease, chronic kidney disease, heart rate and LVEF. Significant covariates were selected with a threshold of 1% in the univariate analysis. Multivariate analysis was conducted using a stepwise method by selecting significant covariates with a threshold of 5%.
Statistical analyses were performed using SAS software (SAS Institute, Inc., Cary, NC, USA).
Results
A total of 7256 patients were screened between September 2013 and December 2014 and baseline treatment adherence scores were analysed and reported for 7117 patients (data extraction July 2016) ( Figure 1 ). Follow-up data were unavailable for 448 patients, and results are reported for the remaining 6669 patients.
The global adherence score at baseline (ACEIs/ARBs, BBs, MRAs and ivabradine) was good in 23% of patients, moderate in 55%, and poor in 22% ( Figure 2 ). The influence of age, sex, ethnicity, co-morbidities and symptoms at baseline is shown in Table 1 . Mean age was similar in groups with good, moderate or poor adherence scores, though there was a non-significant trend towards more patients ≥74 years in the poor adherence group (P = 0.109). Approximately three quarters of patients were male, with a slightly higher proportion of women in the poor adherence group than in the good or moderate groups (P = 0.008). Significantly more patients with a good adherence score were Caucasian than Asian (including Middle East population) (P < 0.001). A significantly higher proportion of patients with a good adherence score had atrial fibrillation/flutter (P < 0.001), coronary artery bypass graft (P = 0.002), diabetes mellitus (P < 0.001), dyslipidaemia (P < 0.001), or history of hypertension (P < 0.001). In addition, a significantly higher proportion had a medical history of asthma or chronic obstructive pulmonary disease (P < 0.001), or chronic kidney disease (P < 0.001). In contrast, a significantly higher proportion of patients with a poor adherence score had a history of cancer than those with a high score (P = 0.043). Amongst patients with a good adherence score, 49.3% had ≥3 co-morbidities, compared to 37.9% in the group with poor adherence score (P < 0.001). Body mass index and systolic and diastolic blood pressure were significantly higher in the group with a good adherence score than in the moderate or poor adherence groups (P < 0.001 for all parameters).
A higher proportion of patients in the good adherence group were in NYHA class I (P < 0.001) compared with patients in the poor adherence group, while slightly more patients in the poor adherence group had NYHA class IV compared with patients in the good adherence group (P < 0.001). Median LVEF was comparable across the high, moderate and poor adherence groups (32.2%, 31.6% and 32.3%, respectively; P = 0.004). Table 2 and Table S2 show adherence score to prescription of medication at baseline. In the group with poor adherence scores, significantly fewer patients were prescribed ACEIs (P < 0.001), BBs (P < 0.001), MRAs (P < 0.001), ivabradine (P < 0.001), diuretics (P < 0.001), anticoagulants (P < 0.001), and statins (P < 0.001). With the exception of BBs, patients in the good adherence group had highest prescribing levels for these classes of drugs. Beta-blockers were most commonly prescribed in the moderate adherence group.
Adherence according to baseline medication
. There was also a trend towards greater use of devices in patients in the good adherence group, with significantly more patients having implantable cardioverter-defibrillators (P = 0.001).
Outcomes at 6 months
Good adherence score at baseline was consistently associated with better clinical outcomes at 6-month follow-up than moderate or poor adherence score ( Table 3 and Figure 3 ). Multivariate analysis showed that poor adherence score was associated with significantly higher all-cause mortality than good adherence score (HR 2.21, 95% CI 1.42-3.44, P = 0.001). Poor adherence score was also associated with significantly higher CV mortality (HR 2.27, 95% CI 1.36-3.77, P = 0.003), HF mortality (HR 2.26, 95% CI 1.21-4.2, P = 0.032), combined HF hospitalization or HF death (HR 1.26, 95% CI 1.08-1.71, P = 0.024) and CV hospitalization or CV death (HR 1.35, 95% CI 1.08-1.69, P = 0.013). In addition, there was a strong trend between poor adherence score and HF hospitalization (HR 1.32, 95% CI 1.04-1.68).
Discussion
Our current analysis showed that (i) adherence to five classes of medications recommended for HFrEF by the ESC at the time the study was initiated 12 was satisfactory; (ii) integration of dosages of these medications into the adherence assessment reduced significantly the proportion of patients with good adherence to 23%; (iii) good adherence to ESC guidelines for the prescription of ACEIs/ARBs, BBs, MRAs and ivabradine, with ≥50% of recommended dosages, was associated with improved clinical outcomes during 6-month follow-up.
Adherence versus outcomes: evidence from observational studies
As demonstrated by our initial analysis and in several observational studies including data from the British National HF audit, adherence to HF guidelines regarding use of appropriate classes of therapy has improved considerably over the past decade from approximately a quarter of prescriptions in 2008 6 to nearly two thirds in 2016. 7, 13 However, our earlier analysis showed that simple calculation of the percentage of treated patients may not be an adequate measure to indicate the quality of healthcare provided for HF patients, and that under-dosing of recommended therapies is a major issue.
In that analysis, the proportion of patients at target dose and ≥50% of target dose was low for most medications (28% and 63% for ACEIs, 7% and 39% for ARBs, 15% and 52% for BBs, 71% and 99% for MRAs, and 27% and 86% for ivabradine). 13 Data from the ESC Heart Failure Long-Term Registry reported in 2013 showed similar trends, with fewer than one-third of patients on guideline-recommended target dosages (29% for ACEIs, 24% for ARBs, 17% for BBs, and 30% for MRAs). 9 Similarly, a recent European survey (BIOSTAT-CHF) conducted in 11 countries and enrolling 2500 patients showed that only a minority of patients reached the target dose of ACEIs and BBs recommended by the ESC guidelines. Several observational studies have explored the association between class adherence to guideline-recommended therapies and clinical outcomes in HF, 8, 16 but the use of dosage as a marker of good adherence has been used less frequently.
15
The Austrian Heart Failure Registry showed that improvement in guideline adherence related to dose escalation towards optimal levels is associated with reduced long-term mortality in ambulatory HFrEF subjects surviving 1 year after registration. 17 Similarly the BIOSTAT-CHF registry showed that patients receiving >50% or recommended doses of ACEIs and BBs had better outcomes than those taking lower doses.
There is therefore evidence from observational studies that dosage of recommended therapies matters.
Dosage and outcomes: evidence from clinical trials
Several randomised clinical trials have explored the relationship between dosage and clinical outcomes. The Assessment of Treatment with Lisinopril and Survival (ATLAS) trial demonstrated that although there were no significant differences in all-cause or CV mortality in patients using higher versus lower doses of lisinopril, there was a lower relative risk of the composite endpoint of total mortality plus hospitalization for any reason, as well as for HF hospitalizations. 10 However, high doses of lisinopril were associated with more adverse events, such as hypotension, dizziness and worsening renal function Failure Assessment (MOCHA) trial evaluated three carvedilol doses in patients with HF. 18 Although this trial was not designed to evaluate the effect of carvedilol on survival, the lowest 6-month mortality was noted in the highest dose group. Finally, the Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan (HEAAL) trial showed that high-dose losartan, compared with low-dose losartan, can reduce mortality and readmission to hospital in patients with HF, supporting the value of up-titrating ARB doses to confer clinical benefit.
11
Other large-scale HF trials have performed post-hoc analyses evaluating the effect of dose on mortality reduction. In the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF), risk reduction was similar in the high-and low-dose subgroups which, at least partly, may be the result of similar beta-blockade as judged from the heart rate response. 19 The results support the idea of an individualised dose-titration regimen, which is guided by patient tolerability and the heart rate response. A similar outcome was reported in a secondary analysis of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II), showing significant and similar relative reductions in mortality by low, moderate and high daily doses of bisoprolol versus the corresponding randomised placebo groups.
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Although post-hoc analyses have limitations, these results together with those of the randomised trials mentioned above suggest that reaching a high dose of recommended medications may favourably influence clinical outcomes. 
Adherence level: a multifactorial situation
Different factors, both medical (patients and physicians) and economic, play an important role in adherence level. Patient factors can influence the adherence level through contraindications, poor tolerability of recommended medications and poor compliance. We did indeed observe that poor adherence was more common in older patients, in patients with the most severe HF (NYHA class IV) and in those with cancer, suggesting that patient frailty may have played a role. In the BIOSTAT-CHF registry, it was observed that patients not reaching recommended doses owing to symptom severity, side effects and non-cardiac organ dysfunction had the highest mortality rate. 15 In the QUALIFY population, we found that more patients had co-morbidities in the good adherence group compared with moderate and poor adherence groups. This observation is counter-intuitive and in contrast with the perception that multimorbidity implies polypharmacy with a consequent poor adherence to treatments. However, research has shown that the relationship between the number of co-morbidities and adherence is inconsistent, due to conflicting results. Some data suggest that having more co-morbidity is related to a lower level of adherence, 21 whereas other studies have shown no impact of co-morbidities on adherence. 22, 23 When analysed, drug adherence appears to be quite a complex phenomenon. A poor adherer to treatments is also a poor adherer to a healthy lifestyle and has characteristics of a phenotype carrying a high risk of premature death. In several RCTs and in a meta-analysis, patient non-adherers to placebo have a nearly 40% higher probability of dying than patient adherers to placebo. 24, 25 . In addition, we could not exclude the fact that some patients were still in the uptitration phase of disease-modifying medications since the lower time window for inclusion in our registry was 1 month after hospitalization for HF. Data from the ESC-HF Long-Term Registry showed that in approximately one-third of patients not achieving target dosages, a drug up-titration was still ongoing, while for about another third of patients not achieving the target, a clear reason was not reported. 9 However, we did not find any significant differences in adherence score and dosages between patients included less than 6 months after previous hospitalization for HF and those included 6 months or later. Finally, if the achieved dosage provides useful information about the quality of care, it is not sufficient in isolation as it may be influenced by the fact that some patients tolerate higher doses because their cardiac reserve is better. Body mass index may also play a role and was, for example, lower in our Asian population than in other patient groups (data not shown).
Physicians' awareness is another important factor. It has been shown that dissemination of guidelines through communication campaigns improves the rate of prescription of recommended medications. 26 In the advanced elderly patient population with HF, physicians' reluctance to provide disease-modifying drugs and focus on symptom relief is well documented. 27 Adherence to recommended clinical practices is also strongly related to access to treatments and affordability, which are the consequence of national economic status. The general organization of healthcare systems and the existence of reimbursement schemes, as well as incentives or obligations to comply with guideline recommendations, play an important role. 28, 29 Inevitably, these factors influence any adherence score, particularly the use of expensive 
Limitations
The population enrolled in our survey was relatively young and this may not necessarily reflect the overall profile of HF in elderly patients.
As with all observational studies, the possibility for unmeasured bias exists, leading to overestimation or underestimation of treatment effects. In particular, adherence behaviour to treatments is known to influence outcomes in itself, as shown by measures of adherence to placebo. 30 Although the registry was conducted in five continents, some geographic areas are underrepresented such as Africa, South America and the United States, as well as some large European countries including the UK and Italy. centres were selected by national coordinators, on a voluntary basis, selection bias cannot be excluded. Recommendations were made to each centre to recruit consecutively but we were unable to verify this procedure.
In particular, we may have underestimated the role of economic factors in countries with low gross national product per capita. This probably explains the low rate of use of devices such as implantable defibrillators and cardiac resynchronization therapy, which have demonstrated benefit in clinical trials.
The vast majority of the investigators were cardiologists, and our survey does not therefore necessarily reflect adherence to guidelines and drug dosage in patients in the care of general practitioners or internists.
We used our adherence score (good, moderate, poor) in relation to prescription and dosages of the five core therapies recommended for HFrEF at the time QUALIFY was initiated. It was therefore based on the ESC HF recommendations published in 2012 12 , and the use of angiotensin receptor neprilysin inhibitor therapy was not captured.
Although drug dosage was integrated into our adherence score, the current analysis of QUALIFY data does not include information about reasons for under-dosing, such as intolerance.
Clinical outcomes were reported by investigators and, although they were given guidance about how these should be assessed, we cannot exclude some variability in reporting.
Conclusion
Our analysis demonstrates that good adherence to contemporary pharmacologic treatment guidelines as determined by prescription of ACEIs/ARBs, BBs, MRAs and ivabradine, in dosages at least 50% of those recommended, is associated with improved mid-term clinical outcomes. Our results reinforce the importance of full implementation of guideline recommendations into clinical practice, and suggest that quality performance metrics for HF in hospitals or healthcare systems should involve global adherence to all medications and dosages. They provide further rationale for performance improvement, and the global use of educational initiatives and disease management programmes to support implementation of guideline-recommended HF therapies, at evidence-based target doses, into clinical practice. Further research is needed to investigate the common causes for failure to adhere to guideline recommendations for drug doses of HF medications, including the potential role of physician-related factors as well as patient-related factors including lack of awareness or intolerance.
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